Resolution Therapeutics Announces Upcoming Scientific Presentations at EASL Congress 2024
- – Late-breaking abstract on extended follow-up data from the MATCH Phase 2 trial accepted for poster presentation
- – Poster presentation on new data highlighting the Company’s discovery platform to differentiate, engineer and cryopreserve macrophages for therapeutic use
Edinburgh and London, UK, 29 May 2024 – Resolution Therapeutics Limited (“Resolution” or “Company”), a clinical-stage biopharmaceutical company pioneering engineered autologous macrophage cell therapies to transform the treatment of inflammatory organ diseases, today announces two abstracts have been accepted as poster presentations at the European Association for the Study of the Liver (EASL) Congress 2024, which is being held in Milan, Italy between June 5-8, 2024.
The first is a late-breaking abstract showcasing extended follow-up data from the MATCH Phase 2 trial. The second abstract highlights new data on Resolution’s discovery platform to differentiate, engineer and cryopreserve macrophages for therapeutic use in patients with end-stage liver disease (ESLD).
